Lantheus Holdings, Inc. (BIT:1LNTH)

Market Cap	4.38B -29.3%
Revenue (ttm)	1.31B +0.5%
Net Income	198.92M -25.2%
EPS	2.90 -21.8%
Shares Out	n/a
PE Ratio	22.04
Forward PE	14.66
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	14
Open	67.70
Previous Close	65.80
Day's Range	67.70 - 68.30
52-Week Range	42.02 - 95.18
Beta	n/a
RSI	52.63
Earnings Date	May 7, 2026

About Lantheus Holdings

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked o...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 1956
• Employees: 1,193
• Stock Exchange: Borsa Italiana
• Ticker Symbol: 1LNTH

Financial Performance

In 2025, Lantheus Holdings's revenue was $1.54 billion, an increase of 0.50% compared to the previous year's $1.53 billion. Earnings were $233.56 million, a decrease of -25.25%.

Financial numbers in USD